Sponsor study identifier
interventional
82
1 country
1
Study Start
March 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 9, 2017
Actual (reported)Study Completion
June 5, 2017
Actual (reported)The purpose of this trial is to investigate a novel treatment for cannabis dependence: cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for moderate cannabis use disorder (DSM-5) will be recruited from the community. Stage one aims to identify the Most Effective Dose (MEDmg) of oral cannabidiol for reducing cannabis use over four treatment weeks. Stage two will determine whether the MED identified in stage 1 can offer an effective treatment for cannabis dependence.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 5, 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 22, 2014
Actual (reported)January 24, 2014
Actual (reported)March 2014
Date type not reportedThis date has not been verified as actual or estimated.
February 9, 2017
Actual (reported)June 5, 2017
Actual (reported)Urinary 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol:creatinine (THC-COOH:creatinine)
This study has two stages. This is the primary endpoint criteria for stage 1.
up to 4 weeks
Number of days abstinent from cannabis
This study has two stages. This is the primary endpoint criteria for stage 1.
up to 4 weeks
Diagnostic and Statistical Manual- 5 (DSM-5) criteria for moderate cannabis dependence
This study has two stages. This is the primary endpoint criteria for stage 2.
up to 4 weeks
Urinary 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol:creatinine(THC-COOH:creatinine) below 50ng/ml
This study has two stages. This is the primary endpoint criteria for stage 2.
week 4
Psychological Wellbeing, Cognition and Endocannabinoids
Up to 28 weeks
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Clinical Psychopharmacology Unit
London, United Kingdom
Lees R, Hines LA, Hindocha C, Baio G, Shaban NDC, Stothart G, Mofeez A, Morgan CJA, Curran HV, Freeman TP. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder. Psychopharmacology (Berl). 2023 Feb;240(2):337-346. doi: 10.1007/s00213-022-06303-5. Epub 2023 Jan 4.
Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, Freeman AM, Lees R, Craft S, Morrison PD, Bloomfield MAP, O'Ryan D, Kinghorn J, Morgan CJA, Mofeez A, Curran HV. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020 Oct;7(10):865-874. doi: 10.1016/S2215-0366(20)30290-X. Epub 2020 Jul 28.
82 participants (actual enrollment reported by the registry).
First Submitted
January 22, 2014
First Posted
January 24, 2014
Study Start
March 2014
Date type not reportedThis date has not been verified as actual or estimated.
Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients
Contact the study team to confirm eligibility.
Primary Completion
February 9, 2017
Actual (reported)Study Completion
June 5, 2017
Actual (reported)Last Updated
October 24, 2018
Record last verified: 2018-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: